English-Video.net comment policy

The comment field is common to all languages

Let's write in your language and use "Google Translate" together

Please refer to informative community guidelines on TED.com

TEDMED 2011

Bill Doyle: Treating cancer with electric fields

Filmed
Views 555,191

Surgery, chemotherapy and radiation are the best-known methods for treating cancer. At TEDMED, Bill Doyle presents a new approach, called Tumor Treating Fields, which uses electric fields to interrupt cancer cell division. Still in its infancy -- and approved for only certain types of cancer -- the treatment comes with one big benefit: quality of life.

- Engineer
With his company Novocure, Bill Doyle works to bring breakthrough medical technologies to doctors and patients. Full bio

Everybody in our society's life is touched by cancer --
00:15
if not personally,
00:18
then through a loved one, a family member,
00:20
colleague, friend.
00:23
And once our lives are touched by cancer,
00:25
we quickly learn
00:28
that there are basically
00:30
three weapons, or three tools, that are available
00:32
to fight the disease:
00:35
surgery, radiation and chemotherapy.
00:38
And once we get involved
00:41
in the therapeutic decisions,
00:44
again either personally
00:47
or with our loved ones and family members,
00:49
we also very quickly learn
00:52
the benefits, the trade-offs and the limitations
00:55
of these tools.
00:58
I'm very thankful to Jay and to Mark
01:00
and the TEDMED team
01:02
for inviting me today
01:04
to describe a fourth tool, a new tool,
01:06
that we call Tumor Treating Fields.
01:09
Tumor Treating Fields
01:12
were invented by Dr. Yoram Palti,
01:14
professor emeritus at the Technion in Israel.
01:17
And they use low-intensity
01:20
electric fields
01:22
to fight cancer.
01:24
To understand how Tumor Treating Fields work,
01:26
we first need to understand
01:29
what are electric fields.
01:31
Let me first address
01:33
a few popular misconceptions.
01:36
First of all, electric fields
01:39
are not an electric current
01:41
that is coursing through the tissue.
01:43
Electric fields
01:46
are not ionizing radiation,
01:48
like X-rays or proton beams,
01:50
that bombard tissue
01:52
to disrupt DNA.
01:54
And electric fields
01:56
are not magnetism.
01:58
What electric fields are
02:00
are a field of forces.
02:02
And these forces
02:05
act on, attract, bodies
02:07
that have an electrical charge.
02:10
The best way to visualize an electric field
02:13
is to think of gravity.
02:15
Gravity is also a field of forces
02:17
that act on masses.
02:20
We can all picture astronauts in space.
02:22
They float freely in three dimensions
02:25
without any forces acting on them.
02:27
But as that space shuttle
02:29
returns to Earth,
02:32
and as the astronauts enter the Earth's gravitational field,
02:34
they begin to see the effects of gravity.
02:37
They begin to be attracted towards Earth.
02:40
And as they land,
02:42
they're fully aligned in the gravitational field.
02:44
We're, of course, all stuck in the Earth's gravitational field right now.
02:46
That's why you're all in your chairs.
02:49
And that's why we have to use our muscle energy
02:52
to stand up, to walk around
02:54
and to lift things.
02:56
In cancer,
02:59
cells rapidly divide
03:01
and lead to uncontrolled tumor growth.
03:03
We can think of a cell
03:06
from an electrical perspective
03:09
as if it's a mini space station.
03:11
And in that space station
03:14
we have the genetic material, the chromosomes,
03:16
within a nucleus.
03:19
And out in the cytoplasmic soup
03:21
we have special proteins
03:23
that are required for cell division
03:25
that float freely in this soup
03:27
in three dimensions.
03:29
Importantly, those special proteins
03:31
are among the most highly charged objects
03:34
in our body.
03:37
As cell division begins
03:39
the nucleus disintegrates,
03:41
the chromosomes line up
03:43
in the middle of the cell
03:45
and those special proteins
03:47
undergo a three-dimensional sequence
03:49
whereby they attach
03:53
and they literally click into place end-on-end
03:55
to form chains.
03:58
These chains
04:00
then progress and attach
04:02
to the genetic material
04:04
and pull the genetic material
04:07
from one cell into two cells.
04:09
And this is exactly how
04:11
one cancer cell becomes two cancer cells,
04:13
two cancer cells become four cancer cells,
04:15
and we have ultimately
04:17
uncontrolled tumor growth.
04:19
Tumor Treating Fields
04:22
use externally placed transducers
04:25
attached to a field generator
04:29
to create an artificial electric field
04:32
on that space station.
04:36
And when that cellular space station
04:39
is within the electric field,
04:42
it acts on those highly charged proteins
04:44
and aligns them.
04:48
And it prevents them from forming those chains,
04:50
those mitotic spindles,
04:53
that are necessary to pull the genetic material
04:55
into the daughter cells.
04:58
What we see is that the cells will attempt to divide
05:00
for several hours.
05:03
And they will either enter into
05:05
this so-called cellular suicide,
05:08
programmed cell death,
05:10
or they will form unhealthy daughter cells
05:12
and enter into apoptosis
05:15
once they have divided.
05:18
And we can observe this.
05:20
What I'm going to show you next
05:22
are two in vitro experiments.
05:24
This is cultures, identical cultures,
05:26
of cervical cancer cells.
05:29
And we've stained these cultures
05:31
with a green florescent dye
05:33
so that we can look at these proteins
05:35
that form these chains.
05:38
The first clip shows
05:40
a normal cell division
05:42
without the Tumor Treating Fields.
05:45
What we see
05:48
are, first of all, a very active culture,
05:50
a lot of divisions,
05:52
and then very clear nuclei
05:54
once the cells have separated.
05:56
And we can see them dividing throughout.
05:58
When we apply the fields --
06:00
again, in the identical time-scale
06:02
to the identical culture --
06:04
you're going to see something different.
06:06
The cells round up for division,
06:08
but they're very static in that position.
06:10
We'll see two cells
06:13
in the upper part of the screen
06:15
attempting to divide.
06:20
The one within the circle manages.
06:22
But see how much of the protein
06:24
is still throughout the nucleus,
06:26
even in the dividing cell.
06:28
The one up there can't divide at all.
06:30
And then this bubbling, this membrane bubbling,
06:32
is the hallmark
06:35
of apoptosis in this cell.
06:37
Formation of healthy mitotic spindles
06:40
is necessary for division
06:44
in all cell types.
06:47
We've applied Tumor Treating Fields
06:49
to over 20 different cancers in the lab,
06:51
and we see this effect
06:54
in all of them.
06:56
Now importantly,
06:59
these Tumor Treating Fields have no effect
07:01
on normal undividing cells.
07:04
10 years ago,
07:06
Dr. Palti founded a company called Novocure
07:08
to develop his discovery
07:11
into a practical therapy for patients.
07:14
In that time, Novocure's developed two systems --
07:17
one system for cancers in the head
07:21
and another system for cancers in the trunk of the body.
07:24
The first cancer that we have focused on
07:27
is the deadly brain cancer, GBM.
07:30
GBM affects about 10,000 people
07:33
in the U.S. each year.
07:36
It's a death sentence.
07:39
The expected five year survival
07:41
is less than five percent.
07:43
And the typical patient
07:45
with optimal therapy
07:47
survives just a little over a year,
07:49
and only about seven months
07:52
from the time that the cancer is first treated
07:54
and then comes back and starts growing again.
07:57
Novocure conducted
08:02
its first phase three randomized trial
08:04
in patients with recurrent GBM.
08:06
So these are patients
08:08
who had received surgery,
08:10
high dose radiation to the head
08:14
and first-line chemotherapy,
08:16
and that had failed and their tumors had grown back.
08:18
We divided the patients into two groups.
08:21
The first group received second-line chemotherapy,
08:24
which is expected to double the life expectancy,
08:27
versus no treatment at all.
08:30
And then the second group
08:32
received only Tumor Treating Field therapy.
08:34
What we saw in that trial
08:37
is that that the life expectancies of both groups --
08:39
so the chemotherapy treated group
08:42
and the Tumor Treating Field group --
08:44
was the same.
08:46
But importantly,
08:48
the Tumor Treating Field group
08:50
suffered none of the side effects
08:53
typical of chemotherapy patients.
08:56
They had no pain,
08:59
suffered none of the infections.
09:01
They had no nausea, diarrhea,
09:04
constipation, fatigue
09:07
that would be expected.
09:10
Based on this trial,
09:12
in April of this year,
09:14
the FDA approved Tumor Treating Fields
09:16
for the treatment of patients
09:19
with recurrent GBM.
09:21
Importantly, it was the first time ever
09:24
that the FDA included
09:27
in their approval of an oncology treatment
09:29
a quality of life claim.
09:32
So I'm going to show you now
09:36
one of the patients
09:39
from this trial.
09:41
Robert Dill-Bundi
09:44
is a famous Swiss cycling champion.
09:46
He won the gold medal in Moscow
09:48
in the 4,000 meter pursuit.
09:50
And five years ago,
09:53
Robert was diagnosed with GBM.
09:56
He received the standard treatments.
09:59
He received surgery.
10:01
He received high dose radiation to the head.
10:04
And he received first-line chemotherapy.
10:07
A year after this treatment --
10:10
in fact, this is his baseline MRI.
10:12
You can see that the black regions
10:15
in the upper right quadrant
10:18
are the areas where he had surgery.
10:20
And a year after that treatment,
10:22
his tumor grew back with a vengeance.
10:24
That cloudy white mass that you see
10:27
is the recurrence of the tumor.
10:30
At this point, he was told by his doctors
10:33
that he had about 3 months to live.
10:36
He entered our trial.
10:39
And here we can see him getting the therapy.
10:41
First of all, these electrodes are noninvasive.
10:44
They're attached to the skin
10:47
in the area of the tumor.
10:49
Here you can see
10:51
that a technician is placing them on there much like bandages.
10:53
The patients learn to do this themselves
10:56
And then the patients
10:59
can undergo all the activities of their daily life.
11:02
There's none of the tiredness.
11:05
There's none of what is called the "chemo head."
11:07
There's no sensation.
11:10
It doesn't interfere
11:12
with computers or electrical equipment.
11:14
And the therapy is delivered continuously
11:17
at home,
11:19
without having to go into the hospital
11:21
either periodically or continually.
11:23
These are Robert's MRIs,
11:26
again, under only TTField treatment.
11:29
This is a therapy that takes time to work.
11:32
It's a medical device;
11:35
it works when it's on.
11:37
But what we can see is, by month six,
11:39
the tumor has responded
11:41
and it's begun to melt away.
11:44
It's still there.
11:47
By month 12,
11:49
we could argue whether
11:51
there's a little bit of material around the edges,
11:53
but it's essentially completely gone.
11:55
It's now five years
11:58
since Robert's diagnosis,
12:00
and he's alive,
12:02
but importantly, he's healthy
12:05
and he's at work.
12:07
I'm going to let him, in this very short clip,
12:09
describe his impressions of the therapy
12:11
in his own words.
12:13
(Video) Robert Dill-Bundi: My quality of life,
12:15
I rate what I have today
12:17
a bit different than what most people would assume.
12:19
I am the happiest, the happiest person in the world.
12:23
And every single morning I appreciate life.
12:28
Every night I fall asleep very well,
12:32
and I am, I repeat,
12:35
the happiest man in the world,
12:38
and I'm thankful I am alive.
12:40
BD: Novocure's also working on lung cancer
12:45
as the second target.
12:48
We've run a phase two trial
12:50
in Switzerland
12:52
on, again, recurrent patients --
12:54
patients who have received standard therapy
12:56
and whose cancer has come back.
12:59
I'm going to show you another clip
13:02
of a woman named Lydia.
13:04
Lydia's a 66 year-old farmer
13:06
in Switzerland.
13:08
She was diagnosed with lung cancer
13:10
five years ago.
13:12
She underwent four different regimes of chemotherapy
13:14
over two years,
13:17
none of which had an effect.
13:19
Her cancer continued to grow.
13:21
Three years ago,
13:23
she entered the Novocure lung cancer trial.
13:25
You can see, in her case,
13:29
she's wearing her transducer arrays,
13:31
one of the front of her chest, one on the back,
13:33
and then the second pair side-to-side over the liver.
13:36
You can see the Tumor Treating Field field generator,
13:39
but importantly you can also see that she is living her life.
13:42
She is managing her farm.
13:45
She's interacting with her kids and her grand kids.
13:47
And when we talked to her,
13:50
she said that when she was undergoing chemotherapy,
13:53
she had to go to the hospital every month for her infusions.
13:55
Her whole family suffered
13:58
as her side effect profile came and went.
14:00
Now she can run
14:02
all of the activities of her farm.
14:04
It's only the beginning.
14:07
(Applause)
14:09
In the lab, we've observed tremendous synergies
14:16
between chemotherapy and Tumor Treating Fields.
14:20
There's research underway now at Harvard Medical School
14:23
to pick the optimum pairs
14:26
to maximize that benefit.
14:28
We also believe that Tumor Treating Fields will work with radiation
14:30
and interrupt the self-repair mechanisms that we have.
14:33
There's now a new research project underway
14:37
at the Karolinska in Sweden
14:39
to prove that hypothesis.
14:41
We have more trials planned
14:43
for lung cancer,
14:45
pancreatic cancer, ovarian cancer
14:47
and breast cancer.
14:49
And I firmly believe
14:51
that in the next 10 years
14:53
Tumor Treating Fields
14:55
will be a weapon available to doctors and patients
14:57
for all of these most-difficult-to-treat solid tumors.
15:00
I'm also very hopeful
15:06
that in the next decades,
15:08
we will make big strides
15:10
on reducing that death rate
15:12
that has been so challenging in this disease.
15:15
Thank you.
15:18
(Applause)
15:20

▲Back to top

About the speaker:

Bill Doyle - Engineer
With his company Novocure, Bill Doyle works to bring breakthrough medical technologies to doctors and patients.

Why you should listen

Bill Doyle is the executive chair of Novocure, a company commercializing a new therapeutic modality for solid tumors using low-intensity electric fields. Recently, Novocure received FDA approval for its first indication, recurrent Glioblastoma Multiforme (GBM), the most virulent form of brain cancer; it is now conducting additional clinical trials.

In 2002, Doyle co-founded medical device venture firm WFD Ventures, which provides financing and business-building expertise to medical device companies with the potential to make a major impact on patient care, working with entrepreneurs, doctors and scientists to improve medical outcomes and maximize the potential of their innovations.

A graduate of MIT, Doyle stablished the MIT FIRST Scholarship for FIRST Robotics Competition participants admitted to MIT.

Watch Jay Walker's onstage Q&A with Bill Doyle >>

More profile about the speaker
Bill Doyle | Speaker | TED.com